Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 2 , Pages 210-213, April 2010

Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy

  • Keon Wook Kang, PhD

      Affiliations

    • BK21 Project Team, College of Pharmacy, Chosun University, Gwangju, South Korea
    • ,
  • Myung-Kwan Chun, PhD

      Affiliations

    • BK21 Project Team, College of Pharmacy, Chosun University, Gwangju, South Korea
    • ,
  • Ok Kim, MS

      Affiliations

    • BK21 Project Team, College of Pharmacy, Chosun University, Gwangju, South Korea
    • ,
  • Robhash Kusam Subedi, MPharm

      Affiliations

    • BK21 Project Team, College of Pharmacy, Chosun University, Gwangju, South Korea
    • ,
  • Sang-Gun Ahn, PhD

      Affiliations

    • Department of Pathology, College of Dentistry, Chosun University, Gwangju, South Korea
    • ,
  • Jung-Hoon Yoon, PhD

      Affiliations

    • Department of Pathology, College of Dentistry, Chosun University, Gwangju, South Korea
    • ,
  • Hoo-Kyun Choi, PhD

      Affiliations

    • BK21 Project Team, College of Pharmacy, Chosun University, Gwangju, South Korea
    • Research Center for Resistant Cells, Chosun University, Gwangju, South Korea
    • Corresponding Author InformationCorresponding author: College of Pharmacy, Chosun University, 375 Seosuk- dong, Dong-gu, Gwangju 501-759, South Korea.

Received 16 September 2009; accepted 18 December 2009. published online 07 January 2010.

Abstract 

In the present study we developed doxorubicin-loaded solid lipid nanoparticles (SLN-Dox) using biocompatible compounds, assessed the in vitro hemolytic effect, and examined their in vivo effects on drug retention and apoptosis intensity in P-glycoprotein-overexpressing MCF-7/ADR cells, a representative Dox-resistant breast cancer cell line. Our SLNs did not show hemolytic activity in human erythrocytes. In comparison with Dox, SLN-Dox efficiently enhanced apoptotic cell death through the higher accumulation of Dox in MCF-7/ADR cells. Therefore, SLN-Dox have potential to serve as a useful therapeutic approach to overcome the chemoresistance of adriamycin-resistant breast cancer.

From the Clinical Editor

Doxorubicin loaded solid lipid nanoparticles (SLN-Dox) were studied in a cell line representative of doxorubicin resistant breast cancer. The nanoparticles did not show hemolytic activity; furthermore, they efficiently enhanced apoptotic cell death through higher accumulation of doxorubicin in cancer cells. This approach may be viable in overcoming the chemoresistance of adriamycin resistant breast cancer.

Key words: Solid lipid nanoparticles, Multidrug resistance, Doxorubicin, P-glycoprotein, Doxorubicin-resistant breast cancer

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Ministry of Education, Science and Technology (MEST) through the Research Center for Resistant Cells (R13-2003-009).

PII: S1549-9634(10)00006-7

doi:10.1016/j.nano.2009.12.006

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 2 , Pages 210-213, April 2010

Article Tools

* Image Usage & Resolution